Fujifilm starts new late-stage trial of Avigan in Japan for COVID-19
Domestic approval for the antiviral drug to treat the coronavirus was dealt a setback in December after a health ministry panel said that trial data was inconclusive.
Drugmakers in Japan struggle to keep pace in COVID-19 medicine race
No applications for drugs specifically tailored to COVID-19 have been filed yet, as domestic pharmaceutical companies have not invested heavily enough in biomedicine.
Fujifilm to restart trial of Avigan to treat COVID-19, report says
Domestic approval of the drug was delayed after a health ministry panel said in December that trial data was inconclusive.
Avigan effectiveness not yet clear, Japan health ministry panel says
The panel will continue its deliberations after determining that the results of clinical tests run by the drug's maker were not adequate to support its efficacy.
The Pharmaceuticals and Medical Devices Agency raised questions about the way tests were performed and the criteria for determining whether symptoms had improved, sources say.
Fujifilm works with Shanghai firm to get Avigan approved in China
Fujifilm Holdings Corp. said on Thursday it has partnered with Shanghai-based Carelink Pharmaceutical Co. to seek approval in China for Avigan to treat COVID-19 and influenza. Carelink will use Fujifilm's data on Avigan's treatment of novel coronavirus infections and influenza to seek imported drug approval ...
Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan
The move comes after a late-stage study showed reduced recovery times for patients with nonsevere symptoms.
Japan denies plan to approve Avigan as COVID-19 treatment in November
In late September, the anti-flu drug's creator said that it would file for regulatory approval as early as October.
Japan planning quickest-ever approval for anti-viral drug Avigan
According to sources, the government had already mapped out the drug's approval process by the time a Fujifilm unit disclosed data from clinical studies.
Avigan maker to seek virus treatment approval after trials show shortened recovery time
Of 156 individuals described as "analysis targets," the median recovery time was 11.9 days in those receiving Avigan compared with 14.7 for patients given a placebo.
Fujifilm completes delayed Avigan clinical test and looks to government application
Fujifilm Holdings Corp. said Monday it has completed delayed clinical tests of Avigan, a potential treatment for COVID-19, paving the way for the application of sales and production of the antivirus drug. Fujifilm Toyama Chemical Co., a subsidiary of Fujifilm Holdings, is conducting analysis of ...
Philippines begins nine-month clinical trial on Avigan in COVID-19 study
The Philippines started nine-month clinical trials for Avigan on Monday to study the efficacy of the Japanese anti-flu drug against the disease caused by the new coronavirus. Health Undersecretary Maria Rosario Vergeire said the clinical trials will include just four hospitals in Metro Manila initially ...
